• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Potential Applications of Remote Limb Ischemic Conditioning for Chronic Cerebral Circulation Insufficiency
Conclusion Due to its long-term and often invisible course, CCCI has received less attention than acute cerebral ischemic stroke. However, without appropriate intervention, CCCI may lead to a variety of adverse events. Because the pathophysiological changes associated with CCCI are complex, pharmacological research in this area has been disappointing. Recent research suggests that RLIC, which is less invasive and more well-tolerated than drug treatment, can activate endogenous protective mechanisms during CCCI. In the present report, we reviewed studies related to CCCI (Table 1), as well as those related to stroke and sta...
Source: Frontiers in Neurology - May 2, 2019 Category: Neurology Source Type: research